Habt ihr heute mal zur Konkurrenz rüber geschaut?
Was haben noch vor kurzer Zeit einige Analysten und Schmierblätter gewarnt und Panik geschürt.
Nach Pfizer noch ein weiterer Rohrkrepierer....
How Does Viking Therapeutics’ Weight-Loss Pill Compare With Competitors?
Viking Therapeutics earlier Tuesday reported mid-stage trial data for its weight-loss pill VK2735, which helped patients lose an average of 12.2% of their body weight after 13 weeks, compared to a 1.3% loss with a placebo.
The once-daily pill VK2735 had lower weight-loss results on average compared to Eli Lilly’s orforglipron, which was tested over 72 weeks. The highest dose of Eli Lilly’s once-daily treatment helped patients lose about 12.4% of their body weight in a late-stage trial, well below analyst expectations of 15%, according to FactSet. Those expectations appeared to trail Novo Nordisk’s success: An oral version of its Wegovy treatment helped patients lose 15% of their body weight on average in a late-stage trial.
forbes.com/sites/tylerroush/2025/08/19/viking-therapeutics-shares-nosedive-toward-worst-day-ever-after-obesity-trial-data/